Indeed, when Soy1 and Lup1 were non-covalently entrapped into the RADA16 self-assembling peptide, the stability of both peptides was significantly improved as well as their capability of inhibiting DPP-IV and ACE, suggesting that this strategy could be a viable platform for targeting metabolic diseases [10]. This evidence concerns the gene FAP and Other metabolic disease.